Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
24 valent pneumococcal conjugate vaccine · 2 trials · 1 indication
Solicited local reactions included redness/erythema, swelling/induration, and pain at injection site
Solicited systemic reactions include fever, headache, fatigue, muscle pain, and joint pain within 7 days of vaccination
Percentage of participants with at least one Treatment Emergent Adverse Event (unsolicited AEs and SAEs)
Percentage of participants with serious adverse events (SAEs) and new onset of chronic illness (NOCIs)
Solicited local reactions include redness/erythema, swelling/induration, and pain at injection site within 7 days after vaccination in each age group
Solicited systemic reactions include fever, headache, fatigue, muscle pain, and joint pain
Percentage of participants in each age group with adverse events (AEs) whose date of onset occurs after the study vaccine and within the 28 days after vaccination.
Percentage of participants with SAEs and NOCIs
| Arm | Type | Description |
|---|---|---|
| VAX-24 Low Dose | EXPERIMENTAL | Participants will receive a single dose of VAX-24 1.1 mcg administered as an intramuscular injection on Day 1. |
| VAX-24 Mid Dose | EXPERIMENTAL | Participants will receive a single dose of VAX-24 2.2 mcg administered as an intramuscular injection on Day 1. |
| VAX-24 Mixed Dose | EXPERIMENTAL | Participants will receive a single dose of VAX-24 2.2 mcg/4.4 mcg administered as an intramuscular injection on Day 1. |
| PCV20 | ACTIVE_COMPARATOR | Participants will receive a single intramuscular injection of the standard dose of PCV20 on Day 1. |
| Name | Type | Description |
|---|---|---|
| 24-Valent Pneumococcal Conjugate Vaccine | BIOLOGICAL | 0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1 |
| Pneumococcal 20-valent Conjugate Vaccine | BIOLOGICAL | 0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1 |
| 24 valent pneumococcal conjugate vaccine | BIOLOGICAL | 0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1 |
| 20 valent pneumococcal conjugate vaccine | BIOLOGICAL | 0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1 |
Inclusion Criteria: * Male or female age 65 or older. * Able and willing to complete the informed consent process. * Available for clinical follow-up through the last study visit at 6 months after the study vaccination. * In good general health as determined by medical history, vital signs, physica...
The 24-valent pneumococcal conjugate vaccine is an investigational vaccine designed to prevent pneumococcal disease. It is being developed by Vaxcyte, Inc. (ticker: PCVX) and is in Phase 2 clinical development. The vaccine is intended for use in adults and older adults to protect against pneumococcal infections.
The 24-valent pneumococcal conjugate vaccine is being studied for the prevention of pneumococcal vaccines, which are infections caused by Streptococcus pneumoniae. It is intended for use in adults, including older adults aged 65 years and above, to provide protection against pneumococcal disease.
The 24-valent pneumococcal conjugate vaccine is being developed by Vaxcyte, Inc., which trades under the ticker symbol PCVX. Vaxcyte is the sponsor of the clinical trials evaluating this vaccine candidate.
The 24-valent pneumococcal conjugate vaccine is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by the FDA. Two clinical trials have been completed, including one Phase 2 trial and one Phase 1 trial, with a total enrollment of 1,042 participants.
Two completed clinical trials have evaluated the 24-valent pneumococcal conjugate vaccine. NCT05297578 was a Phase 2 study in older adults aged 65 years and older, enrolling 207 participants. NCT05266456 was a Phase 1 study in adults aged 18 years and older, enrolling 835 participants. Both were conducted in the United States.
Yes, the 24-valent pneumococcal conjugate vaccine is also known as VAX-24. VAX-24 is the investigational name used by Vaxcyte, Inc. in its clinical trials, including NCT05297578 and NCT05266456, which evaluated its safety, tolerability, and immunogenicity in adults and older adults.